N-benzo[1,3]dioxol-5-yl-2-[5-(1,3-diallyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]acetamide | 574755-05-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: N-benzo[1,3]dioxol-5-yl-2-[5-(1,3-diallyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]acetamide
• 英文别名: N-benzo[1,3]dioxol-5-yl-2-[5-(1,3-diallyl-2,6-dioxo-2,3,6,7-tetrahydro-1h-purin-8-yl)-1-methyl-1h-pyrazol-3-yloxy]-acetamide；N-(1,3-benzodioxol-5-yl)-2-[5-[2,6-dioxo-1,3-bis(prop-2-enyl)-7H-purin-8-yl]-1-methylpyrazol-3-yl]oxyacetamide
• CAS: 574755-05-8
• 化学式: C₂₄H₂₃N₇O₆
• 分子量: 505.49
• InChiKey: ACQDICALDKNTJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  144
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  N-benzo[1,3]dioxol-5-yl-2-[5-(1,3-diallyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]acetamide 在 palladium on activated charcoal 超重氢 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 [3H]-MRE 2029F20
  参考文献：
  名称：

  [3H]-MRE 2029-F20, a selective antagonist radioligand for the human A2B adenosine receptors

  摘要：

  MRE 2029-F20 [N-benzo[1,3]dioxol-5-yl-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]-acetamide] is a selective antagonist ligand of A(2B) adenosine receptors. For use as a radioligand, 1,3-diallyl-xanthine, the precursor of [H-3]-MRE 2029-F20, was synthesized, and tritiated on the allyl groups. [H-3]-MRE 2029-F20 bound to human A(2B) receptors expressed in CHO cells showed a K-D value of 1.65 +/- 0.10 nM and B-max value of 36 +/- 4 fmol/mg protein. [H-3]-MRE2029-F20 represents a useful tool for the pharmacological characterization of human A(2)B adenosine receptor subtype. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.084
• 作为产物：
  描述：

  1,3-二烯丙基-5,6-二氨基尿苷盐酸 在 sodium hydroxide 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N-benzo[1,3]dioxol-5-yl-2-[5-(1,3-diallyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]acetamide
  参考文献：
  名称：

  [3H]-MRE 2029-F20, a selective antagonist radioligand for the human A2B adenosine receptors

  摘要：

  MRE 2029-F20 [N-benzo[1,3]dioxol-5-yl-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]-acetamide] is a selective antagonist ligand of A(2B) adenosine receptors. For use as a radioligand, 1,3-diallyl-xanthine, the precursor of [H-3]-MRE 2029-F20, was synthesized, and tritiated on the allyl groups. [H-3]-MRE 2029-F20 bound to human A(2B) receptors expressed in CHO cells showed a K-D value of 1.65 +/- 0.10 nM and B-max value of 36 +/- 4 fmol/mg protein. [H-3]-MRE2029-F20 represents a useful tool for the pharmacological characterization of human A(2)B adenosine receptor subtype. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.084

文献信息

• 8-Heteroaryl xanthine adenosine A2B receptor antagonists
  申请人：——

  公开号：US20030207879A1

  公开（公告）日：2003-11-06

  The present invention relates generally to compounds of formula (IA): (IA) 1 the preparation thereof, pharmaceutical formulations thereof, and their use in medicine as potent or selective A 2B adenosine receptor antagonists and their uses for treating asthma, autoimmune diseases and retinal vascular diseases.

  本发明总体上涉及公式（IA）的化合物：(IA)1，其制备方法、药物制剂及其在医学中的应用，作为强效或选择性的A2B腺苷受体拮抗剂，以及用于治疗哮喘、自身免疫疾病和视网膜血管疾病的用途。
• METHODS OF TREATING ATHEROSCLEROSIS
  申请人：Leung Edward

  公开号：US20110118276A1

  公开（公告）日：2011-05-19

  The present invention relates to adenosine A 2B receptor antagonists and their use for the prevention and treatment of atherosclerosis by administering to a mammal, in need thereof, a therapeutically effective amount of an adenosine A 2B receptor antagonist, or a pharmaceutically acceptable salt thereof, alone or in combination with other anti-atherosclerotic agents.
• US7205403B2
  申请人：——

  公开号：US7205403B2

  公开（公告）日：2007-04-17
• US7335655B2
  申请人：——

  公开号：US7335655B2

  公开（公告）日：2008-02-26